TCT-843 Transcatheter Aortic Valve Implantation with Edwards SAPIEN XT™ versus Medtronic CoreValve Revalving System® with AccuTrak™: The SAPERE Pilot Study

TCT-843 Transcatheter Aortic Valve Implantation with Edwards SAPIEN XT™ versus Medtronic CoreValve Revalving System® with AccuTrak™: The SAPERE Pilot Study

MCVAT 29.7%; p=0.558), all-cause mortality (3.1% vs. 6.5%; p=0.218), cardiovascular mortality (2.3% vs. 5.4%; p=0.214), myocardial infarction (1.4% vs. 2.2%; p=0.683) or stroke (0.7% vs. 1.1%; p=0.774).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2012-10, Vol.60 (17), p.B245-B245
Hauptverfasser: Buchanan, Gill, Chieffo, Alaide, Montorfano, Matteo, Maisano, Francesco, Latib, Azeem, Cioni, Micaela, Carlino, Mauro, Figini, Filippo, Franzoni, Irene, Durante, Alessandro, Franco, Annalisa, Covello, Remo, Gerli, Chiara, Agricola, Eustachio, La Canna, Giovanni, Spagnolo, Pietro, Alfieri, Ottavio, Colombo, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Drug therapy
Heart attacks
Internal Medicine
Mortality
Studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:MCVAT 29.7%; p=0.558), all-cause mortality (3.1% vs. 6.5%; p=0.218), cardiovascular mortality (2.3% vs. 5.4%; p=0.214), myocardial infarction (1.4% vs. 2.2%; p=0.683) or stroke (0.7% vs. 1.1%; p=0.774).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2012.08.889